Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

  • 1 of 1

The first monoclonal antibody for treating high cholesterol and the first PCSK9 inhibitor is set to launch following a positive opinion from the European Medicines Agency. In the image, a magnification of cholesterol crystals (25x)

Patients with high cholesterol could benefit from evolocumab, a PCSK9 inhibitor, which is set to launch in Europe

Source  PHOTOTAKE Inc. / Alamy